Theialife’s race to bring a childhood myopia treatment to market
Our guest today is Thomas Ruggia, CEO of Theialife, a late-stage biotech developing an oral therapy for pediatric myopia derived from a natural caffeine metabolite.
Our guest today is Thomas Ruggia, CEO of Theialife, a late-stage biotech developing an oral therapy for pediatric myopia derived from a natural caffeine metabolite.